Needham initiated coverage on InflaRx with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for IFRX
Across the 25 sessions after earlier IFRX headlines, the stock closed higher 14 times and lower 10 times, with a median move of 3.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IFRX | SPY |
|---|---|---|---|
| Aug 20, 2026 | InflaRx Announces Participation in September Investor Conferences | -4.7% | -0.8% |
| Aug 6, 2026 | InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones | -2.8% | -0.2% |
| Jul 30, 2026 | InflaRx to Report Second Quarter 2026 Results on August 6, 2026 | +4.2% | +1.7% |
| Jun 30, 2026 | InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos | -1.8% | +0.8% |
| May 13, 2026 | InflaRx upgraded by Raymond James with a new price target | +3.7% | +0.6% |
| May 8, 2026 | InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares | -2.6% | +0.8% |
Quantisnow market dataNASDAQ
IFRX
InflaRx N.V.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2017
Get push alerts for IFRX
Full IFRX profile on Quantisnow Follow IFRX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time